Medication info
LinaGenta Duo Extended-Release Tablet 5/1000 mg (Linagliptin, Metformin Hydrochloride)

LinaGenta Duo Extended-Release Tablet 5/1000 mg (Linagliptin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›1000mg / 1 tabletLinagliptin Micronized›5mg / 1 tablet
Manufacturer / importer
Korea HyuTex Pharmaceutical Co., Ltd.
Appearance
Oval-shaped extended-release tablet, white to almost white, engraved with LD51 on one side
Packaging
28 tablets/box (7 tablets/PTP x 4)
Approval status
Active

MFDS item code 202400621 · Approved 2024.03.22 · Insurance code 649105960

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this drug for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride extended-release 2000 mg. This drug should be taken once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. Take 1 tablet of this drug 5/1000 mg extended-release tablets once daily. Patients taking this drug 2.5/1000 mg extended-release tablets should take 2 tablets at the same time once daily. 1. Patients not currently receiving metformin: The initial dose of this drug is a total daily dose of linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be increased gradually up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this drug is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea or metformin and insulin, an initial dose of this drug consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this drug is administered in combination with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Patients Requiring Caution in Administration). - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this drug, the dose of this drug should correspond to the patient's current doses of linagliptin and extended-release metformin hydrochloride. Renal impairment Because dose adjustment is required according to renal function, assessment of renal function is recommended before and periodically after administration of this drug. No dose adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), defined as creatinine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, this drug may be used with adjustment of the metformin hydrochloride dose as follows, if it is well tolerated and the patient has no other conditions that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, this drug must be discontinued immediately.

Ingredients

Manufacturer
Korea HyuTex Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication helps improve blood sugar control in patients with type 2 diabetes when used alongside diet and exercise. The combination of linagliptin and metformin effectively controls blood sugar, contributing to diabetes management. It is used to reliably maintain patient blood glucose levels.

How to take

Adult dose

The dose of this drug for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride extended-release 2000 mg. This drug should be taken once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. Take 1 tablet of this drug 5/1000 mg extended-release tablets once daily. Patients taking this drug 2.5/1000 mg extended-release tablets should take 2 tablets at the same time once daily. 1. Patients not currently receiving metformin: The initial dose of this drug is a total daily dose of linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be increased gradually up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving metformin - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this drug is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea or metformin and insulin, an initial dose of this drug consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose should be considered. When this drug is administered in combination with insulin or a sulfonylurea, a reduction in the dose of insulin or the sulfonylurea may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Patients Requiring Caution in Administration). - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and the dose adjusted appropriately if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this drug, the dose of this drug should correspond to the patient's current doses of linagliptin and extended-release metformin hydrochloride. Renal impairment Because dose adjustment is required according to renal function, assessment of renal function is recommended before and periodically after administration of this drug. No dose adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), defined as creatinine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, this drug may be used with adjustment of the metformin hydrochloride dose as follows, if it is well tolerated and the patient has no other conditions that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, this drug must be discontinued immediately.

Precautions

This medication can rarely cause severe lactic acidosis or hypoglycemia, so caution is necessary. Do not use this medication if you are allergic to any of its components, or if you have type 1 diabetes, lactic acidosis, diabetic ketoacidosis, severe renal impairment, acute myocardial infarction, or liver dysfunction. Due to the risk of hypoglycemia, blood glucose should be closely monitored when taken with insulin or sulfonylureas, and dosage adjustments may be necessary. Patients with decreased kidney function should regularly check kidney function through blood tests, and this medication should be avoided if kidney function is severely impaired. During acute infections, dehydration, surgery, or the use of radiocontrast iodine, this medication should be temporarily suspended, and restarted only after stabilizing the condition. While taking this medication, acute pancreatitis or skin blistering diseases may occur; if abdominal pain or skin abnormalities appear, consult your doctor immediately. Long-term use may lead to vitamin B12 deficiency, so if symptoms of anemia or neurological issues occur, vitamin B12 levels should be checked. This medication should be swallowed whole without breaking or chewing the tablets, and the tablet coating may appear in the stool, which is normal. Use during pregnancy or breastfeeding is not recommended, and if planning to become pregnant, consult a specialist. Elderly patients often have decreased kidney function, so it is important to carefully check kidney function before and during use, avoiding maximum doses and using appropriate doses.

Side effects

Severe lactic acidosis, hypoglycemia, angioedema, urticaria, lactic acidosis, abnormal vitamin B12 absorption test, hypoglycemia, taste disorder, cough, decreased appetite, diarrhea, constipation, nausea, pancreatitis, vomiting, abdominal pain, oral ulcer, abnormal liver function test, hepatitis, itching, erythema, rash, dermatitis herpetiformis, severe and disabling arthralgia, rhabdomyolysis, increased lipase, increased amylase, nasopharyngitis, hypersensitivity reaction, constipation, epigastric pain, enterocolitis, bowel obstruction, gastritis, herpes zoster, cystitis, acute pyelonephritis, bronchitis, vestibular neuronitis, sepsis, pneumonia, decreased appetite, dehydration, hyperglycemia, cerebral infarction, stuttering, Alzheimer's type dementia, chest pain, fever, facial edema, fatigue, chronic obstructive pulmonary disease, asthma, diabetic foot disease, skin lesions, liver metastasis, acute leukemia, basal cell carcinoma, non-small cell lung cancer, malignant pericardial effusion, gastric cancer, rectal cancer, pancreatic cancer, meniscus injury, pneumoconiosis, congestive heart failure, angina, acute myocardial infarction, unstable angina, cardiac arrest, diabetic retinopathy, acute kidney injury, end-stage kidney disease, acute cholangitis, acute cholecystitis, cholangitis, dizziness, renal transplant failure, anxiety, mood disorder, insomnia, depression, contusion, bone contusion, concussion, bone fracture, hand fracture, hearing loss, erectile dysfunction, goiter, anemia, nausea, gastroesophageal reflux disease, epistaxis, oropharyngeal pain, voice disorder, allergic rhinitis, exertional dyspnea, wet cough, rhinorrhea, pulmonary mass, arthralgia, osteoporosis, arthropathy, musculoskeletal discomfort, myositis, myalgia, soft tissue mass, postmenopausal osteoporosis, rotator cuff syndrome, increased serum triglycerides, increased urinary albumin/creatinine ratio, positive urinary leukocytes, decreased hemoglobin, increased serum potassium, increased serum creatinine, increased serum creatine kinase activity, increased ALT, male-pattern baldness, hyperhidrosis, dermatitis, anxiety, delirium, nocturia, dermatitis, hypertension

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a tightly closed container to prevent air or moisture from entering. It is best to store it at room temperature between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

Oval-shaped extended-release tablet, white to almost white, engraved with LD51 on one side

Package unit

28 tablets/box (7 tablets/PTP x 4)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.